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Abstract. Growth differentiation factor-9 (GDF-9) is a 
family member of bone morphogenetic proteins (BMPs), 
which belong to the TGF-β superfamily. There has been a 
recent surge of interest in the role of growth differentiation 
factors and other BMPs in the development and spread of 
cancer. However, the role of GDF-9 in bladder cancer remains 
unknown. The present study investigated the expression of 
GDF-9 in normal and malignant human bladder tissue and its 
molecular interactions within bladder cancer cells. The expres-
sion of GDF-9 in human bladder tissues and bladder cancer 
cell lines was assessed at both the mRNA and protein levels 
using RT-PCR and immunohistochemistry, respectively. Full-
length GDF-9 cDNA was amplified from normal mammary 
tissues. GDF-9 was overexpressed in bladder cancer cell lines 
using a mammalian expression construct. The effect of GDF-9 
on cellular functions, was examined in bladder cancer cells 
overexpressing GDF-9 using a variety of in vitro assays. In 
normal bladder tissues, stronger staining of GDF-9 was seen in 
transitional cells, both in the cytoplasm and in the nucleus. In 
contrast, the staining of GDF-9 was notably weak or absent in 
cancer cells of tumour tissues. Similarly, the bladder cancer cell 
lines RT112 and EJ138, expressed very low levels of GDF-9. 
Moreover, overexpression of GDF-9 reduced the growth, adhe-
sion and migration of bladder cell lines in vitro. However, the 
overexpression of GDF-9 had little bearing on the invasion of 
bladder cell lines in vitro. In conclusion, GDF-9 is expressed 
at lower levels in human bladder cancer cells compared with 
normal transitional cells of the bladder. GDF-9 levels are 
inversely correlated with the growth, adhesion and migration 
of bladder cancer cells in vitro. The results of the present study 
suggest that GDF-9 is a potential tumour suppressor in human 
bladder cancer.
Introduction
Tumour metastasis is the most significant contributor to the 
mortality of patients with bladder cancer. Although this meta-
static process is poorly understood, several protein families 
have been implicated in the progression and development 
of bladder cancer. One of the these families is known as the 
transforming growth factor β (TGF-β) superfamily (1-3). 
TGF-β has mainly been demonstrated to as a potent growth 
inhibitor in variety of cell types, including bladder cancer 
cells (4). Bone morphogenetic proteins (BMPs), meanwhile, a 
subfamily of the TGF-β superfamily, have been shown to be 
important in the bone formation process and several members 
have been implicated in the pathogenesis of different types of 
cancer (5-9).
BMPs are multi-functional growth factors that can regu-
late a variety of important cellular processes, including cell 
growth, apoptosis, differentiation, and invasion, in a range of 
cell types (10). Subsequently, BMPs were investigated in some 
types of cancer. In human liver cancer, small interfering RNA 
(siRNA)-targeting BMP-2 markedly inhibited the expression 
of BMP-2 in liver cancer cells, and decreased the abilities of 
migration and invasion of liver cancer cells (11). In ovarian 
cancer, BMP-2 efficiently increased the motility of epithe-
lial ovarian cancer cell lines. In contrast, BMP-2 treatment 
decreased the ability of epithelial ovarian cancer cell lines to 
form spheroids indicating an inhibition of cell-cell adhesion. 
The expression of BMP-2 in tumour tissues from patients 
with ovarian cancer was inversely correlated with survival 
(12). In breast cancer, BMP-10 inhibited the aggressiveness of 
breast cancer cells and its reduced expression was correlated 
with poor prognosis (9). In prostate cancer, BMP expression 
has been shown to be variable, with BMP-2, -4, -7, -9 and -10 
expression being reduced compared to normal prostate epithe-
lial cells (13,14). In addition, BMP-6 and -2 have been shown 
to inhibit the growth of prostate cancer cells (15). We have 
recently shown that BMP-9 and -10 can inhibit the growth, 
adhesion, invasion, and migration of prostate cancer cells by 
inducing apoptosis via Smad1, 5 and 8 mediated up-regulation 
of the pro-apoptotic factor Par-4, and the Smad-independent 
pathway, respectively (14,16).
Growth differentiation factor-9 (GDF-9) is a member of the 
BMP family that has been identified as an oocyte growth factor 
with an important role in the regulation of folliculogenesis 
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and ovulation (17). In breast cancer, highly aggressive breast 
cancer cells were shown to express very low levels of GDF-9 
(18). On forced expression of GDF-9, breast cancer cells became 
less invasive (18). Furthermore, another group demonstrated 
up-regulated levels of GDF-9 in an aggressive oral carcinoma 
cell line (19). It has been reported that GDF-9 can promote 
the growth rate of both PC-3 and DU-145 prostate cancer cells 
by protecting the cells from caspase-3-mediated apoptosis, 
suggesting that GDF-9 may aid in the progression of prostate 
cancer by acting as a survival factor (20). Collectively, these 
studies suggest that GDF-9 plays contrasting roles in different 
malignancies. Although GDF-9 has been implicated in disease 
progression of certain tumours, its role in bladder cancer 
remains unknown. In the present study, we first examined the 
expression of GDF-9 in normal and malignant human bladder 
tissues, and the effect of GDF-9 on invasion, growth, adhesion 
and migration of bladder cancer cells.
Materials and methods
Materials, cell lines and tissue samples. All cell lines used 
in this study were obtained from the European Collection 
of Animal Cell Culture (ECACC; Porton Down, Salisbury, 
UK). Cells were routinely maintained in DMEM-F12 medium 
supplemented with 10% foetal bovine serum and antibiotics. 
Polyclonal goat anti-GDF-9 and monoclonal mouse anti-
GAPDH were obtained from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Other reagents or kits were obtained 
from Sigma-Aldrich (Poole, UK) unless otherwise stated. 
Twenty-one bladder samples were collected from patients with 
bladder cancer, immediately after surgery at the University 
Hospital of Wales, Cardiff University School of Medicine, 
including 12 bladder tumour tissues and 9 normal background 
bladder tissues. These tissues were collected immediately 
after radical cystectomy and transurethral resection of bladder 
tumour. All protocols were reviewed and approved by the 
Ethics Committee and all patients gave written informed 
consent.
Immunohistochemical staining procedure for bladder tissues. 
Frozen sections (8-10 µm thickness) were fixed using a mixture 
of acetone and methanol (50:50). The sections were then placed 
in Optimax wash buffer for 5-10 min to rehydrate and incubated 
for 60 min in a blocking solution that contained horse serum 
and probed with the primary antibody (anti-GDF-9a, diluted at 
1:100). Following extensive washing, sections were incubated 
for 30 min with a biotinylated secondary antibody (multilink 
swine anti-goat/mouse/rabbit immunoglobulin, Dako Inc., 
Carpinteria, CA). Following washing, an avidin-biotin complex 
(Vector Laboratories) was applied to the sections followed 
by extensive washing. Subsequently, the diaminobenzidine 
chromogen (Vector Laboratories) was added to the sections, 
which were incubated in the dark for 5 min. Sections were 
then counterstained in Gill's haematoxylin and dehydrated in 
ascending grades of methanol before clearing in xylene and 
mounting under a coverslip.
Construction of GDF-9 expression vectors and transfection. 
These procedures were performed as previously described 
(20). Briefly, the first strand cDNA was synthesized from 
RNA isolated from normal human mammary tissues using 
a DuraScript™ RT-PCR kit. PCR was then used to amplify 
the coding sequence of human GDF-9 using the Extensor 
Hi-Fidelity PCR master mix (ABgene Ltd., Epsom, UK). The 
sequences of the primers are shown in Table I. The verified 
GDF-9 insert was cloned into a mammalian expression plasmid 
vector (pEF/His TOPO® TA plasmid vector; Invitrogen, Inc., 
Paisley, UK). The recombinant plasmid vectors were trans-
formed into chemically competent TOP10 E. coli (Invitrogen, 
Inc.), and the colonies were then analysed. Colonies carrying 
correct recombinant plasmids were amplified and plasmids 
were extracted. Purified GDF-9 transgenes and control plasmid 
vectors were then transfected into RT112 and EJ138 cells indi-
vidually using an Easyjet Plus electroporator (Equibio Ltd., 
Kent, UK). After up to 3 weeks of selection with blasticidin the 
transfectants were verified for their expression of GDF-9 and 
successful clones were used in subsequent studies.
RNA isolation and reverse transcription PCR. RNA was 
isolated using total-RNA isolation reagent (ABgene Ltd.). 
Reverse transcription was performed using the DuraScript™ 
RT-PCR kit, followed by PCR using a REDTaq™ ReadyMix 
PCR reaction mix (primer sequences shown in Table I). 
Cycling conditions were 94˚C for 5 min, followed by 30 cycles 
of 94˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 40 sec. This 
was followed by a final 10 min extension period at 72˚C. The 
products were visualized on 1.5% agarose gel stained with 
ethidium bromide.
Western blot analysis of GDF-9 expression. The protein 
concentration in cell lysates were determined using the DC 
Protein Assay kit (Bio-Rad) and an ELx800™ spectropho-
tometer (Bio-Tek). Equal amounts of protein were separated 
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE), and blotted onto nitrocellulose sheets. Proteins 
were then respectively probed with anti-GDF-9 antibody 
(1:400) or anti-GAPDH (as the loading control) and peroxi-
dase-conjugated secondary antibody, with stringent washings 
between each step. Protein bands were visualized using the 
SuperSignal™ West Dura system (Pierce Biotechnology, Inc., 
Rockford, IL, USA), and photographed using a UVITech 
imager (UVITech, Inc., Cambridge, UK).
In vitro cell growth assay. Cell growth was assessed using a 
previously reported method (24,25). Briefly, the cells were 
plated into a 96-well plate (3,000 cells/well). Cell growth was 
assessed after a period of incubation (up to 5 days). Crystal violet 
was used to stain cells. Following washing, stained crystal was 
extracted with 10% acetic acid and absorbance was determined 
at a wavelength of 540 nm using a spectrophotometer (ELx800).
In vitro invasion assay. This assay was performed according 
to a standard procedure (21-23). Transwell inserts with 8 µm 
pore size were coated with 50 µg Matrigel (BD Matrigel™ 
Basement Membrane Matrix) and air dried. The Matrigel was 
rehydrated before use. Subsequently, 30,000 cells were added 
to each insert, and the same number of cells were loaded into 
another well as control. After 72 h, cells that had migrated 
through the matrix to the other side of the insert were fixed in 
4% formalin and stained with 0.5% (w/v) crystal violet. The 
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stained crystal was extracted with 10% acetic acid and the 
absorbance was determined at a wavelength of 540 nm using a 
spectrophotometer (ELx800).
In vitro cell matrix adhesion assay. Cell matrix adhesion 
was assessed according to a previously described method 
(21-23). A total of 30,000 cells were added to each well of 
a 96-well plate, previously coated with Matrigel (5 µg/well). 
After 40 min of incubation, non-adherent cells were washed 
off using balanced saline solution (BSS) buffer. The remaining 
adherent cells were then fixed and stained with crystal violet. 
The number of adherent cells in random fields were observed 
and counted under a microscope.
Electric cell-substrate impedance sensing (ECIS) based attach-
ment and migration assay. The ECIS Z-Theta instrument and 
96W1E arrays (Applied Biophysics, Inc., Troy, NY, USA) were 
used in the study. We used a recently reported method (26). 
Briefly, the same number of test cells (60,000/well) was added 
to each well of the ECIS arrays. Impedance and resistance of the 
cell layer was immediately recorded for a period of up to 20 h. 
When confluence was reached, the monolayer in each well was 
electrically wounded at 1,400 µA and 6,000 Hz for 30 sec to 
create a 250 µm wound/well. Impedance and resistance of the 
wounded cells as they migrated in the wound was then recorded 
for a period of up to 20 h. Data were analysed using the ECIS 
software, supplied by the manufacturer.
Statistical analysis. All statistical analysis was performed 
using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA). 
Non-normally distributed data were assessed using the 
Mann-Whitney test, while the two sample t-test was used for 
normally distributed data. Differences were considered to be 
statistically significant at P<0.05.
Results
Expression of GDF-9 in human bladder tissues and cell 
lines. In order to estimate the protein levels of GDF-9 in 
human bladder tissues, we conducted immunohistochemical 
analysis using archival normal and malignant bladder tissues. 
Normal bladder transitional cells stained positively for GDF-9 
(Fig. 1A, arrows). The staining was largely confined to the 
cytoplasmic region of the cells. The staining of GDF-9 was 
absent in cancer cells of tumour tissues (Fig. 1B, arrow heads). 
The mRNA expression of GDF-9 was also examined in two 
bladder cancer cell lines and two kidney cancer cell lines using 
RT-PCR. The two bladder cancer cell lines, RT112 and EJ138, 
expressed low levels of GDF-9; interestingly, in the kidney 
cancer cell lines, UMRC-2 and CAKI-2, expression of GDF-9 
was absent (Fig. 1C).
Overexpression of GDF-9 in bladder cancer cells. To investi-
gate the impact of GDF-9 on functions of bladder cancer cells, 
the constructed GDF-9 expression vectors were utilised to 
overexpress GDF-9 in bladder cancer cells. After the selection 
using blasticidin, the expression of GDF-9 in the transfected 
cells was verified using both RT-PCR and Western blotting 
(Fig. 2). Increased GDF-9 expression of both mRNA (Fig. 2A) 
and protein (Fig. 2B) was seen in RT112GDF-9exp, in comparison 
with the controls, RT112WT and RT112pEF. Similarly, over-
expression of GDF-9 was confirmed in EJ138GDF-9exp cells, in 
comparison with EJ138WT and EJ138pEF control cells.
GDF-9 is associated with the growth rate but not with the inva-
sion of bladder cancer cells. RT112 and EJ138 cells forced to 
overexpress GDF-9 displayed a slower growth rate, compared 
with the controls (Fig. 3) (A-RT112 and B-EJ138 cells). Using 
Figure 1. Expression of GDF-9 in bladder cancer. (A and B) Immuno-
histochemical staining of GDF-9 in (A) normal human bladder tissues and 
(B) invasive human bladder cancer tissue. The staining for GDF-9 was mainly 
seen in the cytoplasmic region of the transitional cells (indicated by arrows) 
and was absent in the cancer cells of tumour tissues (arrowheads). (C) The 
mRNA expression of GDF-9 was examined in bladder and kidney cancer cell 
lines using RT-PCR. In bladder cancer cell lines, RT112 and EJ138, expressed 
low levels of GDF-9; in kidney cancer cell lines, UMRC-2 and CAKI-2, the 
expression of GDF-9 was absent.
Table I. Sequences of the primers used in this study.
Primer Sense (5'-3') Antisense (5'-3')
GDF-9 screening ATGGCACGTCCCAACAAAT ATTTGACAGCAGAGGAAAAA
GDF-9 expression GCGCTTTTCAAAGTTCTATC GGTCACATCAATCTGAATCC
GAPDH ATGATATCGCCGCGCTCGTC GCTCGGTGAGGATCTTCA
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the same cells, the invasiveness was further examined in the 
genetically modified cells. However, the overexpression of 
GDF-9 had no significant bearing on the invasion of bladder 
cell lines, RT112 and EJ138 in vitro (Fig. 4).
Effect of GDF-9 overexpression on cell matrix adhesion in 
bladder cancer cells. We first examined the effect of GDF-9 
on the cell matrix adhesion of bladder cancer cell lines. 
Overexpression of GDF-9 significantly inhibited the cell 
matrix adhesion of the RT112 cells (P<0.01 vs. both controls) 
(Fig. 5A). Similarly, compared with EJ138WT and EJ138pEF, the 
number of adherent cells for EJ138GDF-9exp was significantly 
reduced (P<0.01 vs. both controls) (Fig. 5B).
The ECIS system was used to further investigate the effect 
of enhanced expression of GDF-9 on RT112 and EJ138 cell 
adhesion. The attachment capacity was markedly reduced in 
RT112GDF-9exp cells compared with RT112WT and RT112pEF cells 
(Fig. 5C and D). Similarly, the attachment capacity was mark-
edly reduced in EJ138GDF-9exp cells compared with EJ138WT and 
EJ138pEF cells (Fig. 5E and F).
Effect of GDF-9 on migration of bladder cancer cells. The 
effect of GDF-9 on RT112 and EJ138 cellular motility was 
assessed using the ECIS system. The migration capacity 
was markedly reduced in RT112GDF-9exp cells compared with 
RT112WT and RT112pEF cells (Fig. 6A and B). Similarly, the 
migration capacity was markedly reduced in EJ138GDF-9exp cells 
compared with EJ138WT and EJ138pEF cells (Fig. 6C and D).
Discussion
Bladder cancer ranks ninth in worldwide cancer incidence. 
It is the seventh most common malignancy in men and the 
seventeenth in women. It is the fourth most common cancer 
in men and the second most common malignancy affecting 
the genitourinary system (27). Approximately 356,000 new 
bladder cancer cases (274,000 males and 83,000 females) 
Figure 2. Overexpression of GDF-9 in bladder cancer cells. (A) RT-PCR shows 
increased GDF-9 transcripts in the GDF-9-transfected RT112 and EJ138 cells 
compated to the controls. GAPDH was examined as a housekeeping gene. NC 
is negative control. (B) Changes of GDF-9 protein by GDF-9 overexpression 
in the corresponding bladder cancer cells were verified using Western blot 
analysis. GAPDH was used as the housekeeping control.
Figure 3. Effects of GDF-9 on in vitro growth of bladder cancer cells. (A) The 
cell growth rate (third and fifth day, both being normalized by first day) of 
RT112GDF-9exp cells significantly decreased in comparison to the two controls, 
RT112WT and RT112pEF. (B) The cell growth rate of EJ138GDF-9exp cells signifi-
cantly decreased in comparison to the two controls, EJ138WT and EJ138pEF; 
**P<0.01. Shown are representative data from three independent experiments.
Figure 4. Effects of GDF-9 overexpression on the invasion of bladder cancer 
cells. (A) RT112 cells; (B) EJ138 cells. There was no significant difference 
among the three groups. Shown are representative data from three indepen-
dent experiments.
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Figure 5. Effects of GDF-9 on adhesion of bladder cancer cells in vitro. (A) Overexpression of GDF-9 reduced the number of adherent cells in RT112GDF-9exp 
cells. **P<0.01 vs. RT112WT and RT112pEF cells. (B) Overexpression of GDF-9 reduced the number of adherent cells in EJ138GDF-9exp cells. **P<0.01 vs. EJ138WT 
and EJ138pEF cells. (C and D) RT112GDF-9exp cells which overexpressed GDF-9 showed a markedly reduced attachment using an ECIS model. (E and F) EJ138GDF-
9exp cells which overexpressed GDF-9 showed a markedly reduced attachment. ECIS RbA modelling of cell attachment indicated a significant reduction of 
attachment in GDF-9 transfected cells. **P<0.01 vs. wild-type and empty plasmid control cells. All experiments were repeated 3 times.
Figure 6. Effect of GDF-9 on migration of bladder cancer cells. Effect of GDF-9 expression on cell migration as analysed by ECIS (wounding assays). The 
impedance changes during the migration process are shown. (A) The UMRC -2GDF-9exp cells which overexpressed GDF-9 showed a markedly reduced migra-
tion. (B) The EJ138GDF-9exp cells which overexpressed GDF-9 showed a markedly reduced migration. (C) ECIS RbA modelling of cell attachment indicated 
a significant reduction of attachment in GDF-9 transfected RT112GDF-9exp cells. **P<0.01 vs. RT112WT and RT112pEF cells. (D) ECIS RbA modelling of cell 
attachment indicated a significant reduction of attachment in GDF-9 transpfected EJ138GDF-9exp cells. **P<0.01 vs. EJ138WT and EJ138pEF cells. All experiments 
were repeated 3 times.
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were reported worldwide in 2002. At the same time, bladder 
cancer is the most common malignancy of the urinary tract, 
accounting for 90-95% of urothelial carcinomas (28), which 
are also called transitional cell carcinomas (TCCs) (29). TCC 
is a heterogeneous disease with considerable variations of its 
natural history. For example, the five-year survival rate is 
97-98% for patients with a monofocal, well-differentiated and 
small papillary tumour, whereas this could be 0% if patients 
have invasive bladder cancer extending throughout the bladder 
wall and with gross nodal metastases. It is also characterized 
as a carcinoma with multifocality and a high recurrence rate 
(30). At initial diagnosis, 75% patients present with non-muscle-
invasive bladder cancer (NMIBC), the remaining 25% present 
with muscle-invasive bladder cancer (MIBC). The main prob-
lems of NMIBC are recurrence and progression, while MIBC is 
frequently associated with metastatic diseases and is the major 
cause of mortality. In NMIBC, disease recurrence will occur 
in ~50-80% of patients after management with transurethral 
resection (TUR) and intravesical therapy (31). Despite improve-
ments in both early detection and treatment, management of this 
disease remains a challenge.
GDF-9 is a member of the BMP family known as a well-
established follicular growth factor that has been shown to be 
vital during early follicular development (32). BMPs signal via 
two types of specific receptors (BMPRs); type I and II serine/
threonine kinase receptors (33). The BMP signal transduction 
pathway is triggered when a BMP ligand binds to its recep-
tors resulting in induction of either the Smad-dependent or 
Smad-independent pathway. The former is activated by BMPs 
binding to a pre-formed heteromeric receptor complex (PFC) 
(34). This induces the type-II receptor to activate the type-I 
receptor, which in turn phosphorylates the receptor-mediated 
Smads (R-Smads) 1, 5 and 8 or Smads 2 and 3. These activated 
R-Smads then co-localize with Smad 4 and undergo nuclear 
translocation to induce BMP responsive gene expression 
(35). The Smad-independent pathway meanwhile, is activated 
by BMPs that first bind to the type-II receptor, followed by 
recruitment of the type-I receptor (34).
Despite the importance of BMPs in cancers however, the 
role of GDF-9 in cancer remains elusive. The role of GDF-9, 
in tumour progression remains unclear and somewhat contro-
versial. Its tumour suppressive role has been demonstrated 
in human breast cancer (18), but the opposite has been seen 
in oral cancer and prostate cancer (19,20). To the best of our 
knowledge, the current study is the first report to examine the 
staining pattern of GDF-9 in human bladder tissues and to 
assess its impact on the invasion, growth, adhesion and migra-
tion of bladder cancer cells by genetically manipulating the 
expression of GDF-9.
Similarly to human breast cancer (18), GDF-9 was 
expressed at a lower level or was absent in bladder tumour 
cells of bladder tissues. Furthermore, the bladder cancer cell 
lines, RT112 and EJ138, expressed very low levels of GDF-9. 
Moreover, overexpression of GDF-9 reduced the growth, 
adhesion and migration of bladder cell lines in vitro. This is 
in contrast to that observed with prostate cancer cells (8,36). 
This would indicate that in some human tumours, GDF-9 
exists at lower levels, although the opposite may also occur. 
It is interesting to note that GDF-9 is absent in both normal 
bladder transitional cells and bladder cancer cells. The nuclear 
existence of GDF-9 is particularly interesting as it has been 
suggested that the cytoplasmic/nuclear distribution pattern 
of the GDF-9 protein may be a key feature in cancer and an 
important reason in determining the contrasting role of GDF-9 
in different cancer types. The current study further indicates the 
possibility of a nuclear connection in the function of GDF-9. 
Thus, changes in the overall level of staining of GDF-9 in 
bladder cancer cells and in intracellular distribution appear to 
be a feature in human bladder tumour tissues.
In the present study, we employed methods to genetically 
alter the expression of GDF-9 in bladder cancer cells, namely 
the overexpression approach. In clear contrast, forced over-
expression of GDF-9 in two bladder cancer cell lines, RT112 
and EJ138, resulted in a reduction of adhesion and migration. 
This indicates that GDF-9 plays a key role in the control of the 
aggressiveness of bladder cancer cells. The current study has 
also demonstrated that overexpression of GDF-9 resulted in a 
decreased cell growth in vitro. In breast cancer, primary breast 
cancer samples from patients with good predicted prognosis 
had significantly higher levels of GDF-9 compared to samples 
from patients with poor prognosis including those who exhib-
ited metastasis, local recurrence, or had died from breast 
cancer (18). These studies together with evidence presented 
herein, strongly suggest that GDF-9 is a potential tumour 
suppressor in bladder and breast tumours. This suggestion 
is further supported by our in vitro results, in which GDF-9 
exhibited inhibitory effect on growth of bladder cancer cells.
In conclusion, the current study demonstrated the reduced 
expression of GDF-9 in bladder cancer. GDF-9 overexpression 
can suppress the aggressiveness of bladder cancer cells through 
inhibiting cell growth, adhesion and migration. This study 
thus suggests that GDF-9 may be putative tumour suppressor 
in bladder cancer.
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